Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

Summary

Rheumatic disorders are a wide range of conditions which are characterized by chronic pain, with some of the most common conditions being osteoarthritis (OA) and rheumatoid arthritis (RA), and it is estimated that about one in four adults in America are diagnosed with a rheumatic disorder. The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

The rheumatic disorders market is expected to see good growth over the forecast period, increasing from $58.97 billion in 2017 at a compound annual growth rate (CAGR) of 4.46%. The US market accounted for approximately 43% of the global market in the baseline year 2017, and this is projected to remain stable over the forecast period.

The incidence of many indications within the rheumatic disorders therapy area continues to rise and as the global population ages prevalence will increase which is a key driver of market growth. By way of example, the total population living with OA across the seven major markets is expected to increase from 125.76 million in 2017 to 138.44 million in 2024. Market growth will also be driven by the entry of new products to the market, with two drug classes in particular driving strong market growth.

The rheumatic disorders market is dominated by a number of blockbuster drugs, which target tumor necrosis alpha (TNF-α), a key pro-inflammatory cytokine. However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced market dominance.

The therapy market is dominated by top pharmaceutical companies with 18 of the top 20 pharma companies having at least one marketed or pipeline rheumatic disorders product. By 2024, the 10 companies generating the most revenue in the rheumatic disorders therapy area are all top 20 pharmaceutical companies.

The report Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

Forecast projections to 2024 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major drug classes are provided within the report.

Scope

• How is the rheumatic disorders landscape expected to change?
• Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
• Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
• Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
• The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
• What types of companies are involved in the rheumatic disorder therapy area?
• Will the current market leaders retain their dominance over the forecast period?
• How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
• Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the rheumatic disorder drug market
• Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
• Identify which two drug classes will see particularly strong market growth over the forecast period
• See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
• Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals